Compass Pathways
CMPS
About: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Employees: 166
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
191% more call options, than puts
Call options by funds: $6.03M | Put options by funds: $2.07M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
4% more funds holding
Funds holding: 135 [Q1] → 140 (+5) [Q2]
0.7% less ownership
Funds ownership: 56.01% [Q1] → 55.32% (-0.7%) [Q2]
2% less capital invested
Capital invested by funds: $148M [Q1] → $145M (-$3.26M) [Q2]
10% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 39
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Patrick Trucchio
|
$40
|
Buy
Maintained
|
4 Aug 2025 |
|
Canaccord Genuity
Sumant Kulkarni
|
$15
|
Buy
Maintained
|
1 Aug 2025 |
|
Evercore ISI Group
Josh Schimmer
|
$6
|
In-Line
Downgraded
|
23 Jun 2025 |
Financial journalist opinion
Based on 4 articles about CMPS published over the past 30 days
